Dr. David Lanfear and Dr. C. Michael Gibson discuss a new independent, real-world study using U.S. electronic health record data, showing acoramidis was associated with an 18% lower risk of the composite of clinical outcomes compared with tafamidis, including significantly lower rates of cardiovascular death, heart failure, and all-cause hospitalization.